Combination Therapy for Non-Hodgkin Lymphoma Reducing Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-Hodgkin lymphoma (NHL) are often ineffective, particularly for relapsed or refractory cases, and are associated with significant toxicities and side effects.
Innovation Solution
The use of 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, in combination with tafasitamab, obinutuzumab, or tazemetostat, to treat, prevent, or manage NHL.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard chemotherapy agents are used to treat NHL, then DNA synthesis is inhibited to prevent cell division, but severe toxicities and side effects occur including bone marrow depression and immunosuppression
Solution Approach 1:
The patent employs a combination therapy approach that changes the therapeutic parameters by using multiple agents with different mechanisms of action (anti-CD19 monoclonal antibody, BCL-2 inhibitor, and EZH2 inhibitor) rather than relying on a single chemotherapy agent. This multi-target strategy achieves effective tumor cell killing while reducing the severity of individual drug toxicities through synergistic effects.
2Reliability
If multiple chemotherapeutic agents are administered in combination to overcome drug resistance, then treatment efficacy may improve, but toxicities and side effects are intensified
Solution Approach 1:
The patent segments the anti-cancer therapy into three distinct functional components: (1) tafasitamab for immune-mediated tumor cell destruction, (2) venetoclax for blocking anti-apoptotic BCL-2 function, and (3) tazemetostat for epigenetic modulation via EZH2 inhibition. Each component targets a specific molecular pathway, allowing for precise mechanistic division of labor that reduces overlapping toxicities while maintaining comprehensive anti-tumor activity.
3Reliability
If surgery is used to remove neoplastic tissue, then cancer cells can be physically eradicated, but the procedure may be contraindicated due to patient health or may not completely remove all neoplastic tissue
Solution Approach 1:
The patent replaces the mechanical surgical approach with a pharmacological system that uses molecularly targeted agents to selectively destroy tumor cells. The combination of immunotherapy (tafasitamab), apoptosis inhibition (venetoclax), and epigenetic modulation (tazemetostat) creates a biochemical mechanism for tumor eradication that can reach microscopic disease and metastatic sites inaccessible to surgery, while being adaptable to patients who are poor surgical candidates.
4Reliability
If radiation therapy is used to treat NHL, then neoplastic tissue can be targeted, but serious side effects occur and effectiveness is limited to cases where tumor is more sensitive to radiation than normal tissue
Solution Approach 1:
The patent introduces an intermediary mechanism - the immune system - through tafasitamab-mediated antibody-dependent cellular cytotoxicity (ADCC). Rather than directly damaging tumor DNA like radiation, the therapy uses engineered monoclonal antibodies to recruit and activate immune effector cells that selectively recognize and destroy tumor cells expressing CD19, thereby achieving tumor-specific killing with reduced damage to normal tissues.
Data Source
AI summary
Provided herein are methods of using (S)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3- morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione, or an enantiomer, a mixture of enantiomers, a tautomer, an isotopolog, or a pharmaceutically acceptable salt thereof, in combination with tafasitamab, obinutuzumab, or tazemetostat, for treating, preventing or managing non-Hodgkin lymphoma.